Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure

Liu, Mingya; Zhou, Mi; Bao, Yuqian; Xu, Zhen; Li, Huating; Zhang, Hao; Zhu, Wei; Zhang, Jialiang; Xu, Aimin; Wang, Meng; Jia, Weiping

doi:10.1042/cs20120004

Cited by 34 publications

(48 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correlation between elevated serum FABP4 and the deterioration of LV function had previously been reported in non-obese patients who were hospitalised for acutely decompensated HF (Liu et al 2013). However, others have failed to show an association between FABP4 and present (Balci et al 2012) or future (Djousse et al 2013) systolic dysfunction in subjects without prevalent cardiac disease (Liu et al 2013). Altogether, these studies suggest only a marginal contribution of FABP4 to the development of early systolic dysfunction in obese humans.…”

Section: Fabp4 Cardiac Dysfunction and Hfmentioning

confidence: 60%

“…Interestingly, longitudinal systolic and diastolic function was reduced in subjects with high serum FABP4 concentrations. The correlation between elevated serum FABP4 and the deterioration of LV function had previously been reported in non-obese patients who were hospitalised for acutely decompensated HF (Liu et al 2013). However, others have failed to show an association between FABP4 and present (Balci et al 2012) or future (Djousse et al 2013) systolic dysfunction in subjects without prevalent cardiac disease (Liu et al 2013).…”

Section: Fabp4 Cardiac Dysfunction and Hfmentioning

confidence: 94%

“…2). Specifically, FABP4 levels are associated with LVH as well as systolic and diastolic cardiac dysfunction (Balci et al 2012, Engeli et al 2013, Huang et al 2013, Liu et al 2013, Baessler et al 2014, even in an apparently healthy population (Fuseya et al 2014). A positive correlation between FABP4 and both LV dysfunction and myocardial perfusion abnormalities was found in patients with coronary artery disease (Huang et al 2013).…”

Section: Fabp4 Cardiac Dysfunction and Hfmentioning

confidence: 99%

“…FABP4-related heart remodelling and cardiac dysfunction may directly contribute to the development of HF (Liu et al 2013). Liu and coworkers provided the first clinical evidence demonstrating that serum FABP4 concentrations are significantly higher in patients with HF than those in non-HF subjects, and this association was significantly increased with the severity of HF (Liu et al 2013).…”

Section: Fabp4 Cardiac Dysfunction and Hfmentioning

confidence: 99%

“…In particular, obesity has been proposed as one of the main contributors to the onset and progression of HF (Lavie et al 2009). Despite the obesity-related comorbidities that may explain part of this association, a direct relationship between the risk of HF and adipokines has also been proposed (Baldasseroni et al 2012, Djousse et al 2013, Liu et al 2013. Among these adipokines, fatty acidbinding protein 4 (FABP4) has recently been linked to cardiovascular and metabolic diseases.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease

Rodríguez-Calvo¹,

Girona²,

Alegret

et al. 2017

Journal of Endocrinology

101

100

View full text Add to dashboard Cite

Obesity and ectopic fat accumulation in non-adipose tissues are major contributors to heart failure (HF) and cardiovascular disease (CVD). Adipocytes act as endocrine organs by releasing a large number of bioactive molecules into the bloodstream, which participate in a communication network between white adipose tissue and other organs, including the heart. Among these molecules, fatty acid-binding protein 4 (FABP4) has recently been shown to increase cardiometabolic risk. Both clinical and experimental evidence have identified FABP4 as a relevant player in atherosclerosis and coronary artery disease, and it has been directly related to cardiac alterations such as left ventricular hypertrophy (LVH) and both systolic and diastolic cardiac dysfunction. The available interventional studies preclude the establishment of a direct causal role of this molecule in CVD and HF and propose FABP4 as a biomarker rather than as an aetiological factor. However, several experimental reports have suggested that FABP4 may act as a direct contributor to cardiac metabolism and physiopathology, and the pharmacological targeting of FABP4 may restore some of the metabolic alterations that are conducive to CVD and HF. Here, we review the current knowledge regarding FABP4 in the context of HF and CVD as well as the molecular basis by which this protein participates in the regulation of cardiac function.

show abstract

Section: Fabp4 Cardiac Dysfunction and Hfmentioning

confidence: 60%

Section: Fabp4 Cardiac Dysfunction and Hfmentioning

confidence: 94%

Section: Fabp4 Cardiac Dysfunction and Hfmentioning

confidence: 99%

Section: Fabp4 Cardiac Dysfunction and Hfmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease

Rodríguez-Calvo¹,

Girona²,

Alegret

et al. 2017

Journal of Endocrinology

101

100

View full text Add to dashboard Cite

show abstract

Pathophysiological role of fatty acid‐binding protein 4 in Asian patients with heart failure and preserved ejection fraction

et al. 2020

View full text Add to dashboard Cite

Aims Systemic metabolic impairment is the key pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF). Fatty acid-binding protein 4 (FABP4) is highly expressed in adipocytes and secreted in response to lipolytic signals. We hypothesized that circulating FABP4 levels would be elevated in patients with HFpEF, would correlate with cardiac structural and functional abnormalities, and could predict clinical outcomes. Methods and results Serum FABP4 measurements and echocardiography were performed in patients with HFpEF (n = 92) and those with coronary artery disease free of HF (n = 20). Patients were prospectively followed-up for a composite endpoint of all-cause mortality or HF hospitalization. Compared with patients with coronary artery disease, those with HFpEF had higher FABP4 levels [12.5 (9.1-21.0) vs. 43.5 (24.6-77.4) ng/mL, P < 0.0001]. FABP4 levels were associated with cardiac remodelling (left ventricular mass index: r = 0.29, P = 0.002; left atrial volume index: r = 0.40, P < 0.0001), left ventricular systolic and diastolic dysfunction (global longitudinal strain: r = À0.24, P = 0.01; E/e′ ratio: r = 0.29, P = 0.002; and N-terminal pro-B-type natriuretic peptide: r = 0.62, P < 0.0001), and right ventricular dysfunction (tricuspid annular plane systolic excursion: r = À0.43, P < 0.0001). During a median follow-up of 9.1 months, there were 28 primary endpoints in the HFpEF cohort. Event-free survival was significantly decreased in patients with FABP4 levels ≥43.5 ng/mL than in those with FABP4 levels <43.5 ng/mL (P = 0.003). Conclusions Serum FABP4 levels were increased in HFpEF and were associated with cardiac remodelling and dysfunction, and poor outcomes. Thus, FABP4 could be a potential biomarker in the complex pathophysiology of HFpEF.

show abstract

Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure

et al. 2021

View full text Add to dashboard Cite

Aims Few biomarkers to evaluate pathophysiological changes in extra-cardiac tissues have been identified in patients with heart failure (HF). Fatty acid-binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive biomarker for liver injury. However, little is known about the potential role of FABP1 as a biomarker for HF. Methods and results Measurements of serum FABP1 and echocardiography were performed in subjects with compensated HF (n = 162) and control subjects without HF (n = 20). Patients were prospectively followed-up for a composite outcome of all-cause mortality or HF hospitalization. Compared with control subjects, levels of FABP1 were elevated in HF patients [7.9 (6.4-11.7) vs. 17.6 (10.4-28.9) ng/mL, P < 0.0001]. There were significant correlations between FABP1 levels and estimated right ventricular systolic pressure and right atrial pressure. During a median follow-up of 12.0 months, there were 55 primary composite endpoints in the HF cohort. The highest FABP1 tertile was associated with a threefold increased risk of the composite outcome compared with the lowest tertile [95% confidence interval (1.46-6.68), P = 0.003], but other conventional hepatobiliary markers did not predict the outcome. After adjusting for age, sex, atrial fibrillation, and N-terminal pro-B-type natriuretic peptide levels, serum FABP1 remained independently associated with the outcome. Adding FABP1 to the model based on clinical factors and N-terminal pro-B-type natriuretic peptide significantly improved the prognostic value (global χ 2 20.8 vs. 15.5, P = 0.01). Conclusion Serum FABP1 levels are elevated in compensated HF patients, and the magnitude of elevation is independently associated with pulmonary hypertension, right atrial hypertension, and worse clinical outcomes. FABP1 may serve as a new potential biomarker for the assessment of hitherto unrecognized derangement of cardio-hepatic interaction in HF.

show abstract

Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure

Cited by 34 publications

References 30 publications

Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease

Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease

Pathophysiological role of fatty acid‐binding protein 4 in Asian patients with heart failure and preserved ejection fraction

Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure

Contact Info

Product

Resources

About